IPP Bureau
Pfizer and AIF’s Project Parivartan demonstrates progress in addressing antimicrobial resistance
By IPP Bureau - February 22, 2024
Project achieves 30% reduction in hospital acquired infections and 24% reduction in the incidence of multi-drug resistant organisms
Evolving digital landscape within India's healthcare sector: HealthComms 2024 Report
By IPP Bureau - February 22, 2024
These digital avenues have not only revolutionized patient care but also opened up new opportunities for HCPs to build thought leadership in their respective fields
PM Modi inaugurates AIIMS Jammu
By IPP Bureau - February 21, 2024
The fast pace of construction of AIIMS Jammu whose foundation stone laying to inauguration took only 5 years highlights the commitment of the Government
Ayush Ministry to launch project of health screening and management through ayurvedic interventions
By IPP Bureau - February 21, 2024
The project aims at screening the general health condition of the students enrolled in classes 6th to 12th.
Mandaviya inaugurates Vivekananda Cancer & Super Speciality Extension Hospital in Latur
By IPP Bureau - February 21, 2024
The preventive and promotive approach of our traditional health care systems has played a significant role in modern age today
AstraZeneca completes acquisition of Icosavax
By IPP Bureau - February 21, 2024
The acquisition will build on AstraZeneca’s expertise in respiratory syncytial virus
Scandron receives India's first logistics drone type-certification from DGCA
By IPP Bureau - February 20, 2024
The launch of a DGCA Type Approved Logistics Drone facilitates critical medical deliveries to remote regions
European Commission approves Pfizer’s Velsipity for patients with moderately to severely active ulcerative colitis
By IPP Bureau - February 20, 2024
VELSIPITY is the first and only oral advanced ulcerative colitis therapy approved for use in patients 16 years of age or older in the EU
Biocon included in S&P Global Sustainability Yearbook 2024
By IPP Bureau - February 20, 2024
Sustainability is integral to Biocon's business purpose
Briefs: IOL Chemicals and Pharmaceuticals and Auro Peptides
By IPP Bureau - February 20, 2024
IOL Chemicals and Pharmaceuticals’ product approved by CDE of NMPA, China
GSK completes acquisition of Aiolos Bio
By IPP Bureau - February 19, 2024
The acquisition of Aiolos includes AIO-001, a potentially best-in-class, long-acting antithymic stromal lymphopoietin (TSLP) monoclonal antibody
Evonik, University of Mainz to commercialize a new class of PEG lipids for nucleic acid delivery
By IPP Bureau - February 18, 2024
Commercialization of rPEG lipids designed to improve immunogenicity profile for nucleic acid delivery
Precision Optics enters into production and technology licensing agreement for single-use ophthalmic program
By IPP Bureau - February 17, 2024
The agreement sets terms under which POC will manufacture the product or receive royalties
Modi lays foundation stone of AIIMS Rewari in Haryana
By IPP Bureau - February 17, 2024
AIIMS Rewari is a 750-bed hospital complex which includes a 100 seat medical college, a 60 seat nursing college, a 30-bed AYUSH block
Lupin receives approval from USFDA for Minzoya
By IPP Bureau - February 17, 2024
Minzoya Tablets are indicated for use by females of reproductive potential to prevent pregnancy
